Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • NovaBay Pharmaceuticals' Income from Continuing Operations rose 2624.78% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year increase of 5440.86%. This contributed to the annual value of -$7.2 million for FY2024, which is 2507.26% up from last year.
  • NovaBay Pharmaceuticals' Income from Continuing Operations amounted to -$1.3 million in Q3 2025, which was up 2624.78% from -$228000.0 recorded in Q4 2024.
  • NovaBay Pharmaceuticals' Income from Continuing Operations' 5-year high stood at -$111000.0 during Q1 2022, with a 5-year trough of -$8.2 million in Q4 2022.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$1.7 million (2023), whereas its average is -$1.9 million.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Income from Continuing Operations tumbled by 509367.09% in 2022 and then surged by 9444.99% in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$158000.0 in 2021, then crashed by 5093.67% to -$8.2 million in 2022, then soared by 49.94% to -$4.1 million in 2023, then skyrocketed by 94.45% to -$228000.0 in 2024, then plummeted by 450.88% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$228000.0 for Q4 2024, and -$1.7 million during Q3 2024.